· Mainboard · NSE
Price Band
₹0–0
Lot Size
0 shares
Issue Size
Min. Investment
₹0
Indicative, updates through the day
Cap price plus current GMP: ₹0 — arithmetic, not a forecast
Subscription data will appear once bidding opens.
Molbio Diagnostics IPO is a mainboard issue opening for subscription on 10 August 2026, listing on NSE. The issue is priced at ₹0–₹0 per share, and its total size is yet to be confirmed.
No meaningful grey market premium is being quoted for Molbio Diagnostics right now. For a issue still to open, that is common until anchor demand and subscription build — a missing premium is not the same as a negative one, and for a large issue it says more about supply than about the company. More on what the number does and does not mean is in our guide to IPO GMP, or see today’s IPO GMP for every live issue.
The lot size and minimum application will be confirmed in the prospectus. Allotment is handled by KFin Technologies Ltd., with the basis of allotment expected on 13 August 2026 and listing on 17 August 2026. You can later checkallotment status on the registrar’s website using your PAN or application number; if you are not allotted, the funds blocked under ASBA are released rather than debited. The full process is in our guide to IPO allotment.
Figures update through the day and are drawn from exchange and registrar data. Nothing here is investment advice; grey market premium is an unofficial indicator and we are not SEBI-registered analysts.
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities. The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics. As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.
EPS (Pre IPO)
14.56
EPS (Post IPO)
ROE
14.55%
P/E (Pre IPO)
P/E (Post IPO)
Price / Book
Market Cap
-
Molbio Diagnostics Ltd. Address
KFin Technologies Ltd.